Market Cap | 494.58M | P/E | - | EPS this Y | -36.40% | Ern Qtrly Grth | - |
Income | -89.98M | Forward P/E | -7.84 | EPS next Y | -7.10% | 50D Avg Chg | 2.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 42.00% |
Dividend | N/A | Price/Book | 4.26 | EPS next 5Y | - | 52W High Chg | -14.00% |
Recommedations | 1.50 | Quick Ratio | 11.35 | Shares Outstanding | 48.85M | 52W Low Chg | 2,012.00% |
Insider Own | 3.10% | ROA | -31.13% | Shares Float | 41.31M | Beta | 2.40 |
Inst Own | 107.69% | ROE | -48.16% | Shares Shorted/Prior | 6.39M/6.28M | Price | 12.46 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 502,761 | Target Price | 24.33 |
Oper. Margin | - | Earnings Date | Nov 7 | Volume | 164,256 | Change | -1.35% |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
HC Wainwright & Co. | Buy | Sep 17, 24 |
Wells Fargo | Overweight | Aug 12, 24 |
Evercore ISI Group | Outperform | Aug 12, 24 |
HC Wainwright & Co. | Buy | Aug 9, 24 |
Cantor Fitzgerald | Overweight | Jun 21, 24 |
Stifel | Buy | Jun 17, 24 |
HC Wainwright & Co. | Buy | Jun 14, 24 |
HC Wainwright & Co. | Buy | May 24, 24 |
HC Wainwright & Co. | Buy | May 16, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Binder Gwendolyn | See Remarks See Remarks | Jan 19 | Sell | 19.93 | 11,000 | 219,230 | 20,000 | 01/19/24 |
Binder Gwendolyn | See Remarks See Remarks | Jan 19 | Option | 1.01 | 11,000 | 11,110 | 31,000 | 01/19/24 |
Binder Gwendolyn | See Remarks See Remarks | Dec 19 | Sell | 21.99 | 11,000 | 241,890 | 20,000 | 12/19/23 |
Binder Gwendolyn | See Remarks See Remarks | Dec 19 | Option | 1.01 | 11,000 | 11,110 | 31,000 | 12/19/23 |
Binder Gwendolyn | See Remarks See Remarks | Oct 19 | Sell | 13.8 | 11,000 | 151,800 | 20,000 | 10/19/23 |
Binder Gwendolyn | See Remarks See Remarks | Oct 19 | Option | 1.01 | 11,000 | 11,110 | 31,000 | 10/19/23 |
Binder Gwendolyn | See Remarks See Remarks | Jul 19 | Sell | 13.96 | 11,000 | 153,560 | 20,000 | 07/19/23 |
Binder Gwendolyn | See Remarks See Remarks | Jul 19 | Option | 1.01 | 11,000 | 11,110 | 31,000 | 07/19/23 |
Binder Gwendolyn | See Remarks See Remarks | May 19 | Sell | 11.81 | 22,000 | 259,820 | 20,000 | 05/19/23 |
Binder Gwendolyn | See Remarks See Remarks | May 19 | Option | 1.01 | 22,000 | 22,220 | 42,000 | 05/19/23 |
Nichtberger Steven | President & CEO President & CEO | Oct 19 | Buy | 1.2492 | 8,127 | 10,152 | 986,483 | 10/19/22 |
Bollard Catherine | Director Director | Oct 18 | Buy | 0.9935 | 1,000 | 994 | 1,000 | 10/18/22 |
Marda Anup | Chief Financial Offi.. Chief Financial Officer | Oct 18 | Buy | 0.9924 | 50,000 | 49,620 | 50,000 | 10/18/22 |
Simon Mark | Director Director | Oct 18 | Buy | 0.98 | 125,000 | 122,500 | 7,000 | 10/18/22 |
Binder Gwendolyn | See Remarks See Remarks | Oct 18 | Buy | 0.9947 | 20,000 | 19,894 | 20,000 | 10/18/22 |
Nichtberger Steven | President & CEO President & CEO | Oct 18 | Buy | 0.9939 | 141,873 | 141,008 | 978,356 | 10/18/22 |